GuidelineAmerican journal of respiratory and critical care medicine2024
Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.
Guideline in American journal of respiratory and critical care medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Clinical care in interstitial lung disease: a critical appraisal of clinical guidance documents.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- Pooled it
- The 2024 British Society for Rheumatology guideline for management of systemic sclerosis.Rheumatology (Oxford, England) · 2024Guideline
- Nintedanib Therapy Alone and Combined with Mycophenolate in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: Systematic Reviews and Meta-analysis.Annals of the American Thoracic Society · 2024Pooled it
- Tocilizumab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.Annals of the American Thoracic Society · 2024Pooled it
- Rituximab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.Annals of the American Thoracic Society · 2024Pooled it
- Cyclophosphamide in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.Annals of the American Thoracic Society · 2024Pooled it
- Rituximab in systemic sclerosis-associated interstitial lung disease: A systematic review and meta-analysis.Science progressPooled it
- Treatment Response Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.Arthritis care & research · 2025Trial
- Trajectories of forced vital capacity in patients with systemic sclerosis-associated interstitial lung disease.Arthritis research & therapy · 2025Trial
- Continued nintedanib in patients with systemic sclerosis-associated interstitial lung disease: 3-year data from SENSCIS-ON.RMD open · 2025Trial
- Review
- Navigating evidence-based recommendations for the management of systemic sclerosis.Nature reviews. Rheumatology · 2026Review
- Early effects of antifibrotic therapy on respiratory muscle stiffness and dyspnea in SSc-ILD: a shear wave elastography study.Internal and emergency medicine · 2026Article
- Radiomic analysis of high-resolution computed tomography predicts interstitial lung disease progression and mortality in systemic sclerosis.Rheumatology (Oxford, England) · 2026Article
- Advances in pharmacotherapy for fibrotic interstitial lung disease.Medical review (2021) · 2026Review
- Pulmonary hypertension associated with interstitial lung disease: a state-of-the-art review.The European respiratory journal · 2026Review
- International travel considerations for patients with systemic autoimmune inflammatory diseases in the era of novel immunosuppressive therapies.Rheumatology international · 2026Review
- The Convergence of Fibrosis and Granulomatous Inflammation: A Case Series on the Diagnostic and Therapeutic Challenges of Systemic Sclerosis and Sarcoidosis Overlap Syndrome.Diagnostics (Basel, Switzerland) · 2026Article
- Combination therapy with mycophenolate mofetil, nintedanib, and tocilizumab in a patient with progressive systemic sclerosis-associated interstitial lung disease : A case report and a literature review.Zeitschrift fur Rheumatologie · 2026Review
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.